Medicus Pharma (NASDAQ:MDCX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research report released on Thursday,Benzinga reports. The firm currently has a $27.00 price target on the stock.

A number of other research firms also recently weighed in on MDCX. D Boral Capital raised Medicus Pharma to a “strong-buy” rating in a report on Monday, April 14th. Maxim Group increased their price objective on shares of Medicus Pharma from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Finally, Wall Street Zen cut shares of Medicus Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Medicus Pharma has a consensus rating of “Buy” and an average target price of $23.50.

Medicus Pharma Stock Performance

Shares of Medicus Pharma stock opened at $2.45 on Thursday. The firm’s 50 day moving average is $4.51. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). On average, research analysts anticipate that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medicus Pharma news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $7.72, for a total transaction of $579,000.00. Following the sale, the insider now owns 3,248,741 shares in the company, valued at approximately $25,080,280.52. This trade represents a 2.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Investors Weigh In On Medicus Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDCX. Private Advisor Group LLC bought a new stake in shares of Medicus Pharma during the 1st quarter valued at $211,000. Armistice Capital LLC bought a new stake in Medicus Pharma during the first quarter valued at about $4,710,000. Finally, Interchange Capital Partners LLC bought a new stake in Medicus Pharma during the fourth quarter valued at about $3,628,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.